Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureAli Moradi, Rahul Winayak, Sumanta Kumar Pal
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy
10.1053/j.gastro.2022.10.018 · 2023
Interaction between microbiota and immunity in health and disease
10.1038/s41422-020-0332-7 · 2020
Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions
10.1016/j.cell.2022.09.005 · 2022
A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors
10.1016/j.cell.2022.09.015 · 2022
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide
10.1126/science.1240537 · 2013
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment
10.1126/science.1240527 · 2013
Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a prospective, longitudinal study
10.1158/1078-0432.ccr-20-3445 · 2021
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma
10.1038/s41467-020-18127-y · 2020
Targeting regorafenib-induced toxicity through inhibition of gut microbial β-glucuronidases
10.1021/acschembio.9b00663 · 2019
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
10.1126/science.aan4236 · 2018
Gut microbiome affects the response to immunotherapy in non-small cell lung cancer
10.1111/1759-7714.15303 · 2024
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
10.1038/s41591-022-01694-6 · 2022
Gut microbiome and immune checkpoint inhibitor toxicity
10.1016/j.ejca.2025.115221 · 2025
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
10.1126/science.aaz7015 · 2021
Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis
10.3389/fimmu.2023.1070076 · 2023
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
10.1126/science.aan3706 · 2018
Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients
10.1126/science.abf3363 · 2021
Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor
10.1016/j.chom.2024.06.010 · 2024
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme
10.1126/science.1191175 · 2010
Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation
10.1038/s42003-021-01741-x · 2021
Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
10.1111/1759-7714.13711 · 2021
The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer
10.1002/ctm2.1312 · 2023
Gut microbiome in association with chemotherapy-induced toxicities among patients with breast cancer
10.1002/cncr.35229 · 2024
The interplay between gut bacteria and targeted therapies: implications for future cancer treatments
10.1186/s10020-025-01108-6 · 2025
Gut microbiota and sunitinib-induced diarrhea in metastatic renal cell carcinoma: a pilot study
10.2147/cmar.s328451 · 2021
Differences in the intestinal microbiome associated with diarrhea during lenvatinib treatment for hepatocellular carcinoma
10.1159/000524298 · 2023
Relationship between adverse events and microbiomes in advanced hepatocellular carcinoma patients treated with sorafenib
10.21873/anticanres.13996 · 2020
Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer
2022
Association of gut microbiota and immune gene expression with response to targeted therapy in BRAF mutated melanoma
10.1038/s41598-025-11054-2 · 2025
Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
10.1186/s12885-022-10050-3 · 2022
The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC
10.1016/j.jtho.2019.04.007 · 2019
Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors
10.1016/j.eururo.2020.07.011 · 2020
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
10.1126/science.aao3290 · 2018
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
10.1038/s41591-021-01655-5 · 2022
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
10.1126/science.abc3421 · 2020
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
10.1126/science.aac4255 · 2015
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
10.1093/annonc/mdy103 · 2018
A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors
10.3389/fonc.2023.1075593 · 2023
Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
10.1093/cid/ciw118 · 2016
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
10.1038/ncomms10391 · 2016
Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer
10.1158/2326-6066.cir-20-0051 · doi-reference
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
10.1038/s41591-024-03086-4 · doi-reference
First-in-class microbial ecosystem therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)
10.1016/j.annonc.2023.02.011 · doi-reference
Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity
10.1158/2159-8290.cd-24-0066 · doi-reference
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors
10.1007/s10637-025-01573-0 · doi-reference
The mechanisms and therapeutic potential of the microbiome-immune interface in cancer
10.1007/s44340-025-00031-0 · doi-reference
Oral compound probiotic supplements can improve the quality of life for patients with lung cancer during chemotherapy: a randomized placebo-controlled study
10.1111/1759-7714.15177 · doi-reference
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study
10.1038/sj.bjc.6603990 · doi-reference
Randomized double-blind, placebo-controlled multicenter phase 3 study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12 Lactobacillus rhamnosus LGG in colorectal cancer patients
10.3389/fonc.2023.1168654 · doi-reference
Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial
10.1016/j.ijrobp.2007.11.009 · doi-reference
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer
10.1002/ijc.34842 · doi-reference
Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma
10.1002/cam4.3569 · doi-reference
Effect of inulin and fructo-oligosaccharide on the prevention of acute radiation enteritis in patients with gynecological cancer and impact on quality-of-life: a randomized, double-blind, placebo-controlled trial
10.1038/ejcn.2015.192 · doi-reference
Prebiotic-induced anti-tumor immunity attenuates tumor growth
10.1016/j.celrep.2020.01.035 · doi-reference
Association of a mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma
10.1001/jamaoncol.2022.7753 · doi-reference
Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics
10.1038/nrgastro.2017.75 · doi-reference
Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation
10.1016/j.chom.2018.01.003 · doi-reference
Early antibiotic use after fecal microbiota transplantation increases risk of treatment failure
10.1093/cid/cix684 · doi-reference
Fecal microbiota transplantation in refractory immune-mediated colitis: case series and review of the literature
10.3390/ph18111719 · doi-reference
Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial
10.1038/s41591-025-04183-8 · doi-reference
Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial
10.1038/s41591-025-04189-2 · doi-reference
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
10.1038/s41591-025-04186-5 · doi-reference
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
10.1038/s41591-023-02453-x · doi-reference
Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response
10.1016/j.medj.2024.10.007 · doi-reference
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
10.1038/s41591-023-02234-6 · doi-reference
Gut microbiota modulation through Akkermansia spp supplementation increases CAR T-cell potency
10.1158/2159-8290.cd-24-1230 · doi-reference
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
10.1038/s41591-022-01702-9 · doi-reference
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
10.1126/science.abb5920 · doi-reference
Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis
10.1126/scitranslmed.abq4006 · doi-reference
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
10.1038/s41591-018-0238-9 · doi-reference
The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non-small cell lung cancer
10.1158/2326-6066.cir-20-0196 · doi-reference
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
10.1093/annonc/mdx108 · doi-reference